Red cell alloantibodies in beta-thalassaemia major patients’ blood referring to the regional blood transfusion center of Tehran, Iran

Introduction: Thalassemia is associated with a genetic decline in the rate of synthesis of one or more types of natural hemoglobin polypeptide chains. One of the major complications in thalassemia patients is alloimmunization, which is antibody production by the patient against transfused red blood cells (RBCs). These RBCs are unknown by the recipient and the formed antibodies against them are called alloantibodies. This study aimed to evaluate the frequency of alloantibodies against RBCs in beta-thalassemia patients referred to Tehran Regional Blood Transfusion Center. Methods: In this study, antibody screening tests (Dia-cell I, II, and III) were performed on 184 thalassemia patients. An identification test by the Dia panel consisting of 11 different O RBCs groups to examine sera with Dia cells (I, II, or III) was performed. Results: In our study, males and females patients comprised 66 (35.87%) and 118 (64.13%), respectively, of whom 116 (63%) had alloimmunization. In addition, 68 thalassemia subjects (37%) lacked alloantibodies. Among 184 patients with beta-thalassemia major, anti-K (Kell system), anti-D, and anti-E (Rhesus system) had the most abundant alloantibody variants with an incidence of 24 (13%), 11 (5.98%), and 10 (5.4%), respectively. Conclusion: Before RBC transfusion, regular RBC antigen phenotypes, as well as problem-solving of alloantibody production by receiving compatible blood for Kell and RH subgroups, are suggested for all cases of transfusion-derived thalassemia.

[1]  R. Putzulu,et al.  The role of molecular typing and perfect match transfusion in sickle cell disease and thalassaemia: An innovative transfusion strategy. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[2]  K. Eliaçık,et al.  Frequency of red cell allo- and autoimmunization in patients with transfusion-dependent beta thalassemia and affecting factors. , 2014, The Turkish journal of pediatrics.

[3]  D. Canatan.  The Thalassemia Center of Antalya State Hospital: 15 Years of Experience (1994 to 2008) , 2013, Journal of pediatric hematology/oncology.

[4]  M. Maghsudlu,et al.  Blood Transfusion and Alloimmunization in Patients with Thalassemia: Multicenter Study , 2011, Pediatric hematology and oncology.

[5]  S. Ragab,et al.  Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients , 2010, Archives of medical science : AMS.

[6]  A. Keyvan,et al.  Evaluation of Transfusion Reactions in Thalassemic Patients Referred to the Thehran Adult Thalssemia Clinic , 2008 .

[7]  A. Eder,et al.  Noninfectious complications of blood transfusion. , 2009, Archives of pathology & laboratory medicine.

[8]  M. Karimi,et al.  RBC alloimmunization in blood transfusion‐dependent β‐thalassemia patients in southern Iran , 2007, International journal of laboratory hematology.

[9]  D. Liang,et al.  Alloimmunization among patients with transfusion‐dependent thalassemia in Taiwan , 2006, Transfusion medicine.

[10]  A. Brand,et al.  Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? , 2006, Transfusion.

[11]  R. Davenport.  Pathophysiology of hemolytic transfusion reactions. , 2005, Seminars in hematology.

[12]  E. P. Dellinger,et al.  Infectious and immunologic consequences of blood transfusion , 2004, Critical care.

[13]  S. Al-Shemmari,et al.  RBC alloimmunization and autoimmunization among transfusion‐dependent Arab thalassemia patients , 2003, Transfusion.

[14]  N. Blumberg,et al.  WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization , 2003, Transfusion.

[15]  B. Wonke.  Clinical management of -Thalassemia major , 2001 .

[16]  H. Klein,et al.  Autoantibody formation in the alloimmunized red blood cell recipient: clinical and laboratory implications. , 2001, Archives of internal medicine.

[17]  H. Haak,et al.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases , 1999, Transfusion.

[18]  N. Olivieri.  5 Thalassaemia: clinical management , 1998 .

[19]  N. Olivieri.  Thalassaemia: clinical management. , 1998, Bailliere's clinical haematology.

[20]  P. Rebulla.  Blood transfusion in beta thalassaemia major , 1995, Transfusion medicine.

[21]  D. Weatherall.  The Molecular Basis for Phenotypic Diversity of Genetic Disease , 1995, Annals of the New York Academy of Sciences.

[22]  A. Karaklis,et al.  Alloimmunization to Red Cell Antigens in Thalassemia: Comparative Study of Usual versus Better‐Match Transfusion Programmes , 1987, Vox sanguinis.